ClinicalTrials.gg
CompletedNCT05735249Updated May 1, 2026Results posted

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

A Phase 1 interventional study of ARN-75039 oral capsules and Placebo in Healthy Adult Participants, sponsored by Arisan Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Arisan Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

ARN-75039 is proposed for the treatment of subjects with LASV infection, Lassa hemorrhagic fever, a potentially fatal human disease associated with Lassa viruses, with the most significant unmet medical need. ARN-75039-101 study was a randomized, double-blind, placebo-controlled study that assessed the safety, tolerability, and PK of escalating single and multiple doses of ARN 75039 when administered by the oral route in healthy adult subjects in six single ascending dose (SAD - Part 1) cohorts and five multiple ascending dose (MAD - Part 2) cohorts.

Read the detailed description

In Part 1 (SAD), eight subjects per cohort (except for 10 subjects in cohort 3, evaluating the effects of food) were enrolled to receive the study drug orally in the fed state. Within each cohort of eight subjects, the first two subjects (Sentinel) were randomly assigned in a 1:1 ratio to receive a single dose of ARN-75039 capsules or placebo (microcrystalline cellulose). After the medical monitor reviewed the first 3 days of blinded safety for these subjects, an additional 6 subjects (the remaining cohort) were randomly assigned in a 5:1 (active: placebo) ratio. Within the food-effect cohort of 10 subjects, the first two subjects (Sentinel) were randomly assigned in a 1:1 ratio to receive ARN-75039 capsules or a placebo in the fasted state. After the medical monitor reviewed the first three days of blinded safety for these subjects, an additional 8 subjects (the rest of the cohort) were randomly assigned in a 7:1 (active: placebo) ratio.

The Part 2 (MAD) dosing plan consisted of two days of lead-in doses followed by eight days of maintenance dosing. All doses were administered twice daily (BID), approximately 10 hours apart:

  • Day 1: a single dose of ARN-75039 3 times (3×) the maintenance dose, followed by a single dose of 2× the maintenance dose
  • Day 2: Two doses of 2× the maintenance dose
  • Day 3 through Day 10: BID dosing of the maintenance dose Dose escalation within the SAD and MAD portions was performed after review by the Safety Monitoring Committee (SMC) of blinded safety and available PK data from all subjects in all available cohorts through study Day 8. The MAD part of the study was initiated after the safety and PK data from the SAD part were reviewed by the Food and Drug Administration (FDA), and the Sponsor and FDA determined that it was safe to proceed. The SMC also evaluated the PK profile of ARN-75039, when available, to determine if a threshold exposure associated with potential anti-viral activity was achieved, which corresponded to the recommended Phase 2 dose (RP2D).

The study was conducted in three study periods (Screening Period, Treatment Period, and Follow-up Period). During the Treatment Period, safety was assessed at each study visit, and PK assessments were conducted at specific time points per the assessment schedule. Subjects who received at least one dose of the study drug were instructed and encouraged to complete all study visits. Subjects in the Treatment period had spans of residency at the study site as well as ambulatory periods in each part of the study. Subjects returned to the study site for follow-up evaluations according to the Schedule of Assessments (SOA) during the Treatment Period. After completing the Treatment Period, subjects entered the Safety Follow-up Period, consisting of 14 days for the SAD part of the study and 28 days for the MAD part, culminating in an End-of-study (EOS) visit. For subjects who withdrew from the study prematurely, the EOS visit was conducted within seven days after the last study drug dose.

02

Conditions studied

  • Healthy Adult Participants

Keywords

  • Phase 1
  • Safety
  • Tolerability
  • Randomized
  • Double-Blind
  • Single-Ascending Dose
  • Multiple-Ascending Dose
03

In context

Lead sponsor

Arisan Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is male or female, age 18 to 55 years, inclusive, at Screening.
  2. (BMI) between 18.5 and 35 kg/m2, inclusive, at Screening.
  3. In good general health, determined by no findings in the opinion of the Investigator from medical history, physical examination, 12-lead (ECG), clinical laboratory findings, and vital signs at Screening and Day -1 or 1.
  4. , hematocrit, white blood cell count, , and count results within the laboratory reference range at Screening; subjects with Gilbert's disease with associated abnormalities of liver function tests are eligible for enrollment. Tests may be repeated at the discretion of the Investigator to confirm abnormalities.
  5. Estimated (eGFR) based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation of ≥ 80 mL/min/1.73m2 at Screening
  6. Females of must practice effective per national regulatory guidelines for clinical trials from Screening, throughout the study and for 28 days after the EOS visit.
  7. Females of childbearing potential must have a negative pregnancy test at Screening and within 24 hours prior to dosing of study drug; for subjects, a blood sample will also be tested for follicle stimulating hormone (FSH) to confirm post-menopausal status (as verified by an FSH of ≥40). Surgically sterile females are eligible; however, proof via medical records will be required.
  8. Males must agree to not donate sperm and/or to use condoms during sexual intercourse from the time of the first study drug administration and for 90 days following the last dose of study drug, and females must agree not to donate eggs from the time of the first study drug administration and for 60 days following the last dose of study drug.
  9. Must be Willing and able to comply with measures to avoid photosensitivity reactions (i.e., avoidance of outdoor sun exposure and tanning; consistent use of long sleeve shirts, long pants, hats, and sunglasses; consistent use of SPF 75 or greater sunscreen when outdoors) from Day 1 through Day 8 in Part 1 and through Day 25 in Part 2.
  10. Able to provide .
  11. Willing and able to comply with this protocol and be available for the entire duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Any underlying illness in the opinion of the Investigator.
  2. Poor venous access.
  3. Inability to ingest all capsules of a multi-capsule dose within 5 minutes of ingestion of the first capsule.
  4. Prior exposure to ARN-75039.
  5. Positive serology for virus (HBV), virus (HCV), or (HIV) at Screening; subjects with adequately treated HCV are eligible for enrollment.
  6. Positive test for SARS-CoV-2 infection on Day -1.
  7. Consumption of Seville oranges, grapefruit or grapefruit juice within 72 hours prior to Day 1 or during the study.
  8. History of drug or alcohol abuse within 1 year of Screening in the opinion of the investigator, or a positive test for drugs of abuse or alcohol at Screening or Day -1.
  9. Use of any prescription or over-the-counter (OTC) medications, including food supplements, vitamins, herbal medications (e.g., St. John's wort), and cannabis, with the exception of medications and as needed (prn) acetaminophen or paracetamol (not exceeding 2 grams/day) within 7 days prior to study drug administration and through the EOS visit.
  10. History of , except adequately treated basal cell carcinoma or in situ carcinoma of the uterine cervix.
  11. Smoking greater than 20 cigarettes, cigars, cigarillos or E-cigarettes per week in the 3 months prior to study drug administration or during the study.
  12. Any female who is pregnant or breastfeeding, or any female who is planning to become pregnant during the study and safety follow-up period.
  13. Any reason or condition that, in the investigator's opinion, may compromise study participation, present a safety risk to the subject, or may confound the interpretation of the study results.
  14. A duration corrected for heart rate by Fridericia's formula (QTcF) > 450 millisecond (msec) based on either single or averaged QTcF values of triplicate ECGs obtained over a 3-minute interval (at Screening).
  15. Blood product donation within 30 days before Screening.
  16. unwilling to consume breakfast and dinner on study drug administration days
  17. Currently enrolled in another device or drug study, or less than 30 days or 5 half-lives of the prior investigational agent (whichever is longer) or plans to enroll in another investigational device or drug study during the course of this study.

    Part 2 (MAD) only:

  18. History of:

    1. Structural abnormality of the gastrointestinal (GI) tract or a disease or history of a condition that can affect GI motility
    2. Inflammatory bowel disease (even if treated and currently in remission)
    3. Diverticulitis or any other chronic condition such as chronic pancreatitis, polycystic kidney disease, ovarian cysts, endometriosis, lactose intolerance that was associated with abdominal pain or discomfort and confounded the assessments in this trial.
    4. Chronic idiopathic diarrhea
    5. Formally diagnosed with colonic inertia or conditions that were associated with constipation: pseudo-obstruction, colonic inertia, megacolon, megarectum, bowel obstruction, descending perineum syndrome, solitary rectal ulcer syndrome, systemic sclerosis, lower tract evacuation disorders, functional outlet delay (e.g., rectal prolapse, anismus, etc.)
  19. Current active peptic ulcer disease (i.e., disease that was not adequately treated or stable with therapy.)
  20. Potential central nervous system cause of constipation (e.g., Parkinson's disease, spinal cord injury, and multiple sclerosis.)
  21. Subject currently had both unexplained and clinically significant alarm symptoms (lower GI bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia or any unexplained anemia, or weight loss) or systemic signs of infection or colitis.
  22. Subjects who did not expel at least 80% (19 or more) of the markers after the Sitzmarks® colonic transit test administered during the screening period.
  23. History of chronic/generalized pruritus and/or severe skin rash of unknown origin
  24. Subjects diagnosed with Type 1 or Type 2 diabetes, or with a blood glucose value >125 mg/dL during screening period.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    ARN-75039 oral capsules

    Escalating single or multiple doses of ARN-75039 oral capsules

    Drug: ARN-75039 oral capsules

  • Placebo comparator
    Placebo (microcrystalline cellulose)

    Specified weight of placebo (microcrystalline cellulose) corresponding to the dose of ARN-75039 within the same cohort and encapsulating it in a HPMC capsule prior to dosing.

    Drug: Placebo

Interventions

  • active oral study drug prepared and administered as oral capsules

    Also known as: ARN75039

  • DrugPlacebo

    Given at frequency and amounts matching ARN- 75039 dosing regimen

    Also known as: Matching placebo oral capsules (Cohorts 1 through 11)

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    A treatment-emergent adverse event (TEAE) was defined as any adverse event that began or worsened after administration of the study drug (ARN-75039 or placebo) through the End-of-Study visit.

    Time frame: From first dose through the End-of-Study (EOS) visit: Part 1 (SAD), through Day 15/EOS; Food-effect cohort, through the second treatment period and Day 29/EOS; Part 2 (MAD), from Day 1 through Day 39/EOS.

  2. Incidence of Treatment-Emergent Serious Adverse Events (TESAEs)

    Number of participants with at least one treatment-emergent Serious adverse event (TESAE). A TESAE is any adverse event that starts or worsens after administration of study drug (ARN-75039 or placebo).

    Time frame: From first dose through the End-of-Study (EOS) visit: Part 1 (SAD), through Day 15/EOS; Food-effect cohort, through the second treatment period and Day 29/EOS; Part 2 (MAD), from Day 1 through Day 39/EOS.

Secondary outcomes

  1. Part 1-SAD: Cmax

    Maximum Observed Plasma Concentrations of ARN-75039 (Cmax); Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.

    Time frame: Day 1 predose and at 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 168 (Day 8), and 336 (Day 15/EOS) hours postdose.

  2. Part 1-SAD: Tmax

    PK of ARN-75039 in healthy subjects as assessed by time to reach Cmax (Tmax) towards the determination of the optimal PK dose

    Time frame: Day 1 predose and at 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 168 (Day 8), and 336 (Day 15/EOS) hours postdose.

  3. Part 1-SAD: Terminal Half-life

    PK of ARN-75039 in healthy subjects as assessed by terminal elimination half-life (T1/2)

    Time frame: Derived from plasma samples collected from Day 1 predose through 336 hours (Day 15/EOS) postdose.

  4. Part 1-SAD: AUC

    PK of ARN-75039 in healthy subjects as assessed by plasma exposure (AUC), determination of the optimal PK dose

    Time frame: Day 1 predose and at 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 168 (Day 8), and 336 (Day 15/EOS) hours postdose.

  5. Part 2-MAD: Cmax0-10h

    Maximum Plasma Concentrations of ARN-75039 at 1 and 10 days. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen

    Time frame: Day 1 and Day 10: predose and at 0.5, 1, 2, 4, 6, 8, and 10 hours after the morning dose.

  6. Part 2-MAD: Tmax0-10h.

    Time to maximum ARN-75039 concentration. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.

    Time frame: Day 1 and Day 10: predose and at 0.5, 1, 2, 4, 6, 8, and 10 hours after the morning dose.

  7. Part 2-MAD: AUC0-10h

    Area Under the Concentration Time Profile. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.

    Time frame: Day 1 and Day 10: predose and at 0.5, 1, 2, 4, 6, 8, and 10 hours after the morning dose.

07

Results

Posted May 1, 2026
Limitations and caveats
Phase 1 safety and pharmacokinetic study in healthy adults; not designed to assess efficacy.

Participant flow

This study was conducted at a single site in the United States from January 23, 2023 (first participant visit) to March 28, 2025 (last participant visit). The study included Screening, Treatment, and Follow-up periods.

Participant flow — Overall Study
MilestonePart 1- SAD: Cohort 1 (30mg, Fed)Part 1- SAD: Cohort 2 (100mg, Fed)Part 1- SAD: Cohort 3 (300mg, Fed and Fasted for FE)Part 1- SAD: Cohort 4 (600mg, Fed)Part 1- SAD: Cohort 5 (1200mg, Fed)Part 1- SAD: Cohort 6 (2000mg, Fed)Part 1- SAD: Placebo (Fed and Fasted)Part 2- MAD: Cohort 7 (Fed)Part 2- MAD: Cohort 8 (Fed)Part 2- MAD: Cohort 9 (Fed)Part 2- MAD: Cohort 10 (Fed)Part 2- MAD: Cohort 11 (Fed)Part 2- MAD: Placebo (Fed)
Started668666126667712
Completed668665116656611
Not completed0000011001111
Withdrew: Adverse event0000001000111
Withdrew: Lost to follow-up0000010000000
Withdrew: Withdrawal by subject0000000001000

Outcome measures

SecondaryPart 1-SAD: Cmax

Maximum Observed Plasma Concentrations of ARN-75039 (Cmax); Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.

Time frame:
Day 1 predose and at 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 168 (Day 8), and 336 (Day 15/EOS) hours postdose.
Reported as:
Mean · ng/mL
Part 1-SAD: Cmax
ng/mLCohort 1 (30mg, Fed)Cohort 2 (100mg, Fed)Cohort 3 (300mg, Fed)Cohort 3 (300mg, Fasted)Cohort 4 (600mg, Fed)Cohort 5 (1200mg, Fed)Cohort 6 (2000mg, Fed)
Part 1-SAD: Cmax141.3 ± 48.359442.0 ± 134.761281 ± 445.04722.1 ± 281.301962 ± 762.012687 ± 1252.22933 ± 554.24
SecondaryPart 1-SAD: Tmax

PK of ARN-75039 in healthy subjects as assessed by time to reach Cmax (Tmax) towards the determination of the optimal PK dose

Time frame:
Day 1 predose and at 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 168 (Day 8), and 336 (Day 15/EOS) hours postdose.
Reported as:
Mean · h
Part 1-SAD: Tmax
hCohort 1 (30mg, Fed)Cohort 2 (100mg, Fed)Cohort 3 (300mg, Fed)Cohort 3 (300mg, Fasted)Cohort 4 (600mg, Fed)Cohort 5 (1200mg, Fed)Cohort 6 (2000mg, Fed)
Part 1-SAD: Tmax5.67 ± 0.816.03 ± 0.075.51 ± 0.934.27 ± 1.656.01 ± 3.335.67 ± 0.826.67 ± 2.74
PrimaryIncidence of Treatment-Emergent Adverse Events (TEAEs)

A treatment-emergent adverse event (TEAE) was defined as any adverse event that began or worsened after administration of the study drug (ARN-75039 or placebo) through the End-of-Study visit.

Time frame:
From first dose through the End-of-Study (EOS) visit: Part 1 (SAD), through Day 15/EOS; Food-effect cohort, through the second treatment period and Day 29/EOS; Part 2 (MAD), from Day 1 through Day 39/EOS.
Reported as:
Count of participants · Participants
Incidence of Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPart 1-SAD: Cohort 1 (30mg, Fed)Part 1-SAD: Cohort 2 (100mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fasted)Part 1-SAD: Cohort 4 (600mg, Fed)Part 1-SAD: Cohort 5 (1200mg, Fed)Part 1-SAD: Cohort 6 (2000mg, Fed)Part 1-SAD: Placebo (Fed)Part 1-SAD: Placebo (Fasted)Part 2-MAD: Cohort 7 (Fed)Part 2: MAD: Cohort 8 (Fed)Part 2-MAD: Cohort 9 (Fed)Part 2-MAD: Cohort 10 (Fed)Part 2-MAD: Cohort 11 (Fed)Part 2-MAD: Placebo (Fed)
Incidence of Treatment-Emergent Adverse Events (TEAEs)125022440224655
PrimaryIncidence of Treatment-Emergent Serious Adverse Events (TESAEs)

Number of participants with at least one treatment-emergent Serious adverse event (TESAE). A TESAE is any adverse event that starts or worsens after administration of study drug (ARN-75039 or placebo).

Time frame:
From first dose through the End-of-Study (EOS) visit: Part 1 (SAD), through Day 15/EOS; Food-effect cohort, through the second treatment period and Day 29/EOS; Part 2 (MAD), from Day 1 through Day 39/EOS.
Reported as:
Count of participants · Participants
Incidence of Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsPart 1-SAD: Cohort 1 (30mg, Fed)Part 1-SAD: Cohort 2 (100mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fasted)Part 1-SAD: Cohort 4 (600mg, Fed)Part 1-SAD: Cohort 5 (1200mg, Fed)Part 1-SAD: Cohort 6 (2000mg, Fed)Part 1-SAD: Placebo (Fed)Part 1-SAD: Placebo (Fasted)Part 2-MAD: Cohort 7 (Fed)Part 2: MAD: Cohort 8 (Fed)Part 2-MAD: Cohort 9 (Fed)Part 2-MAD: Cohort 10Part 2-MAD: Cohort 11Part 2-MAD: Placebo
Incidence of Treatment-Emergent Serious Adverse Events (TESAEs)000000000000000
SecondaryPart 1-SAD: Terminal Half-life

PK of ARN-75039 in healthy subjects as assessed by terminal elimination half-life (T1/2)

Time frame:
Derived from plasma samples collected from Day 1 predose through 336 hours (Day 15/EOS) postdose.
Reported as:
Mean · h
Part 1-SAD: Terminal Half-life
hCohort 1 (30mg, Fed)Cohort 2 (100mg, Fed)Cohort 3 (300mg, Fed)Cohort 3 (300 mg, Fasted)Cohort 4 (600 mg, Fed)Cohort 5 (1200 mg, Fed)Cohort 6 (2000mg, Fed)
Part 1-SAD: Terminal Half-life4.27 ± 06.24 ± 1.9715.43 ± 10.4510.13 ± 9.66137.3 ± 62.6798 ± 39.8290.34 ± 46.94
SecondaryPart 1-SAD: AUC

PK of ARN-75039 in healthy subjects as assessed by plasma exposure (AUC), determination of the optimal PK dose

Time frame:
Day 1 predose and at 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 168 (Day 8), and 336 (Day 15/EOS) hours postdose.
Reported as:
Mean · h*ng/mL
Part 1-SAD: AUC
h*ng/mLCohort 1 (30mg, Fed)Cohort 2 (100mg, Fed)Cohort 3 (300mg, Fed)Cohort 3 (300mg, Fasted)Cohort 4 (600mg, Fed)Cohort 5 (1200mg, Fed)Cohort 6 (2000mg, Fed)
AUC 0-t952.3 ± 313.614184 ± 1276.915170 ± 4816.37593 ± 3833.832710 ± 6233.143650 ± 2214956780 ± 14333
AUC 0-∞1448 ± 05004 ± 1266.715830 ± 4982.78083 ± 4132.038740 ± 8194.148860 ± 2370462860 ± 16776
SecondaryPart 2-MAD: Cmax0-10h

Maximum Plasma Concentrations of ARN-75039 at 1 and 10 days. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen

Time frame:
Day 1 and Day 10: predose and at 0.5, 1, 2, 4, 6, 8, and 10 hours after the morning dose.
Reported as:
Mean · ng/mL
Part 2-MAD: Cmax0-10h
ng/mLCohort 7 (Fed)Cohort 8 (Fed)Cohort 9 (Fed)Cohort 10 (Fed)Cohort 11 (Fed)
Cmax (day 1)144.7 ± 34.82304.8 ± 45.86678.8 ± 296.86723.7 ± 139.61639 ± 615.63
Cmax (day 10)76.42 ± 16.94159.5 ± 27.60346.3 ± 129.40333.0 ± 73.54800.0 ± 270.33
SecondaryPart 2-MAD: Tmax0-10h.

Time to maximum ARN-75039 concentration. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.

Time frame:
Day 1 and Day 10: predose and at 0.5, 1, 2, 4, 6, 8, and 10 hours after the morning dose.
Reported as:
Mean · h
Part 2-MAD: Tmax0-10h.
hCohort 7 (Fed)Cohort 8 (Fed)Cohort 9 (Fed)Cohort 10 (Fed)Cohort 11 (Fed)
Tmax0-10h (day 1)4.7 ± 1.643.67 ± 1.513.20 ± 1.104.30 ± 0.754.00 ± 0.00
Tmax0-10h (day 10)5.01 ± 1.105.35 ± 1.045.01 ± 1.164.67 ± 1.045.01 ± 1.10
SecondaryPart 2-MAD: AUC0-10h

Area Under the Concentration Time Profile. Pharmacokinetic endpoints included standard noncompartmental parameters following single and multiple ascending oral doses of ARN-75039. The effect of food on ARN-75039 pharmacokinetics was evaluated following administration under fed and fasted conditions. Integrated safety and PK data were used to determine the recommended Phase 2 dose (RP2D) and dosing regimen.

Time frame:
Day 1 and Day 10: predose and at 0.5, 1, 2, 4, 6, 8, and 10 hours after the morning dose.
Reported as:
Mean · h*ng/mL
Part 2-MAD: AUC0-10h
h*ng/mLCohort 7 (Fed)Cohort 8 (Fed)Cohort 9 (Fed)Cohort 10 (Fed)Cohort 11 (Fed)
AUC0-10h (day 1)821.8 ± 145.641651 ± 228.573805 ± 1439.54042 ± 876.969039 ± 2833.5
AUC0-10h (day 10)548.7 ± 78.3211197 ± 183.862322 ± 815.212433 ± 461.716270 ± 2264.2

Adverse events

Collected over From first dose through the End-of-Study visit: Part 1 (SAD), through Day 15/EOS (14 days after dosing); Food-effect cohort, through Day 29/EOS; Part 2 (MAD), through Day 39/EOS (28 days after the last dose on Day 10).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1-SAD: Cohort 1 (30mg, Fed)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1-SAD: Cohort 2 (100mg, Fed)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1-SAD: Cohort 3 (300mg, Fed)0/8 (0%)0/8 (0%)5/8 (62.5%)
Part 1-SAD: Cohort 3 (300mg, Fasted)0/8 (0%)0/8 (0%)0/8 (0%)
Part 1-SAD: Cohort 4 (600mg, Fed)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1-SAD: Cohort 5 (1200mg, Fed)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1-SAD: Cohort 6 (2000mg, Fed)0/6 (0%)0/6 (0%)4/6 (66.7%)
Part 1-SAD: Placebo (Fed)0/12 (0%)0/12 (0%)4/12 (33.3%)
Part 1-SAD: Placebo (Fasted)0/1 (0%)0/1 (0%)0/1 (0%)
Part 2-MAD: Cohort 7 (Fed)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 2: MAD: Cohort 8 (Fed)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 2-MAD: Cohort 9 (Fed)0/6 (0%)0/6 (0%)4/6 (66.7%)
Part 2-MAD: Cohort 10 (Fed)0/7 (0%)0/7 (0%)6/7 (85.7%)
Part 2-MAD: Cohort 11 (Fed)0/7 (0%)0/7 (0%)5/7 (71.4%)
Part 2-MAD: Placebo (Fed)0/12 (0%)0/12 (0%)5/12 (41.7%)
Most frequent other events
Showing 10 of 40
Most frequent other events
EventPart 1-SAD: Cohort 1 (30mg, Fed)Part 1-SAD: Cohort 2 (100mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fasted)Part 1-SAD: Cohort 4 (600mg, Fed)Part 1-SAD: Cohort 5 (1200mg, Fed)Part 1-SAD: Cohort 6 (2000mg, Fed)Part 1-SAD: Placebo (Fed)Part 1-SAD: Placebo (Fasted)Part 2-MAD: Cohort 7 (Fed)Part 2: MAD: Cohort 8 (Fed)Part 2-MAD: Cohort 9 (Fed)Part 2-MAD: Cohort 10 (Fed)Part 2-MAD: Cohort 11 (Fed)Part 2-MAD: Placebo (Fed)
Medical device site reactionGeneral disorders0/60/61/80/81/60/60/60/120/10/61/63/65/73/73/12
NauseaGastrointestinal disorders0/60/60/80/80/60/63/60/120/10/61/60/60/70/70/12
VomitingGastrointestinal disorders0/60/60/80/80/60/62/60/120/10/60/60/61/70/70/12
HeadacheNervous system disorders0/60/60/80/80/62/60/60/120/10/60/60/60/71/71/12
Dermatitis contactSkin and subcutaneous tissue disorders0/60/62/80/80/60/60/60/120/10/60/60/60/70/70/12
Feeling hotGeneral disorders0/60/60/80/80/60/61/60/120/10/60/60/60/70/71/12
Swelling faceGeneral disorders0/60/60/80/80/60/60/60/120/10/61/60/60/70/70/12
Vessel puncture site bruiseGeneral disorders0/60/61/80/80/60/60/60/120/10/61/60/60/70/70/12
Vessel puncture site painGeneral disorders0/61/60/80/80/60/60/60/120/10/60/60/60/70/70/12
Abnormal faecesGastrointestinal disorders0/60/60/80/80/60/60/60/120/10/61/60/61/70/70/12

Baseline characteristics

The Safety Population included all subjects who received at least one dose of study drug (ARN-75039 or placebo). Baseline characteristics were summarized separately for Part 1 (SAD) and Part 2 (MAD) Safety Populations. Overall pooled descriptive statistics across both study parts were not calculated in the CSR for continuous variables (Age, BMI, weight, and height); therefore, overall values are not presented.

Age, Continuous
Age, Continuous(Years)Part 1-SAD: Cohort 1 (30mg, Fed)Part 1-SAD: Cohort 2 (100mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect)Part 1-SAD: Cohort 4 (600mg, Fed)Part 1-SAD: Cohort 5 (1200mg, Fed)Part 1-SAD: Cohort 6 (2000mg, Fed)Part 1-SAD: Placebo (Fed and Fasted for Food Effect)Part 2-MAD: Cohort 7 (Fed)Part 2: MAD: Cohort 8 (Fed)Part 2-MAD: Cohort 9 (Fed)Part 2-MAD: Cohort 10 (Fed)Part 2-MAD: Cohort 11 (Fed)Part 2-MAD: Placebo (Fed)Total
Mean43.7 ± 10.9833.2 ± 12.0939.6 ± 8.6345.5 ± 10.3929.5 ± 6.8330.0 ± 7.7737.3 ± 10.0942.5 ± 7.7141.2 ± 5.6441.5 ± 11.4134.9 ± 7.3836.4 ± 7.1433.0 ± 8.8337.3 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Part 1-SAD: Cohort 1 (30mg, Fed)Part 1-SAD: Cohort 2 (100mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect)Part 1-SAD: Cohort 4 (600mg, Fed)Part 1-SAD: Cohort 5 (1200mg, Fed)Part 1-SAD: Cohort 6 (2000mg, Fed)Part 1-SAD: Placebo (Fed and Fasted for Food Effect)Part 2-MAD: Cohort 7 (Fed)Part 2: MAD: Cohort 8 (Fed)Part 2-MAD: Cohort 9 (Fed)Part 2-MAD: Cohort 10 (Fed)Part 2-MAD: Cohort 11 (Fed)Part 2-MAD: Placebo (Fed)Total
Female334313621564546
Male334353645113748
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1-SAD: Cohort 1 (30mg, Fed)Part 1-SAD: Cohort 2 (100mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect)Part 1-SAD: Cohort 4 (600mg, Fed)Part 1-SAD: Cohort 5 (1200mg, Fed)Part 1-SAD: Cohort 6 (2000mg, Fed)Part 1-SAD: Placebo (Fed and Fasted for Food Effect)Part 2-MAD: Cohort 7 (Fed)Part 2: MAD: Cohort 8 (Fed)Part 2-MAD: Cohort 9 (Fed)Part 2-MAD: Cohort 10 (Fed)Part 2-MAD: Cohort 11 (Fed)Part 2-MAD: Placebo (Fed)Total
American Indian or Alaska Native00000000000000
Asian01000000010204
Native Hawaiian or Other Pacific Islander00000000000000
Black or African American222332634342642
White436333632223343
More than one race00000100000023
Unknown or Not Reported00000000001012
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1-SAD: Cohort 1 (30mg, Fed)Part 1-SAD: Cohort 2 (100mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect)Part 1-SAD: Cohort 4 (600mg, Fed)Part 1-SAD: Cohort 5 (1200mg, Fed)Part 1-SAD: Cohort 6 (2000mg, Fed)Part 1-SAD: Placebo (Fed and Fasted for Food Effect)Part 2-MAD: Cohort 7 (Fed)Part 2: MAD: Cohort 8 (Fed)Part 2-MAD: Cohort 9 (Fed)Part 2-MAD: Cohort 10 (Fed)Part 2-MAD: Cohort 11 (Fed)Part 2-MAD: Placebo (Fed)Total
Hispanic or Latino100100220021312
Not Hispanic or Latino5685661046656982
Unknown or Not Reported00000000000000
Body Mass Index (BMI)
Body Mass Index (BMI)(Kg/m^2)Part 1-SAD: Cohort 1 (30mg, Fed)Part 1-SAD: Cohort 2 (100mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect)Part 1-SAD: Cohort 4 (600mg, Fed)Part 1-SAD: Cohort 5 (1200mg, Fed)Part 1-SAD: Cohort 6 (2000mg, Fed)Part 1-SAD: Placebo (Fed and Fasted for Food Effect)Part 2-MAD: Cohort 7 (Fed)Part 2: MAD: Cohort 8 (Fed)Part 2-MAD: Cohort 9 (Fed)Part 2-MAD: Cohort 10 (Fed)Part 2-MAD: Cohort 11 (Fed)Part 2-MAD: Placebo (Fed)Total
Mean27.18 ± 2.9326.23 ± 3.5729.13 ± 3.8827.47 ± 3.3926.68 ± 1.6225.10 ± 5.4126.18 ± 3.25826.27 ± 2.6727.63 ± 1.8126.75 ± 2.2530.67 ± 2.2927.49 ± 1.9826.90 ± 3.0227.2 ± 3.19
Weight
Weight(kg)Part 1-SAD: Cohort 1 (30mg, Fed)Part 1-SAD: Cohort 2 (100mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect)Part 1-SAD: Cohort 4 (600mg, Fed)Part 1-SAD: Cohort 5 (1200mg, Fed)Part 1-SAD: Cohort 6 (2000mg, Fed)Part 1-SAD: Placebo (Fed and Fasted for Food Effect)Part 2-MAD: Cohort 7 (Fed)Part 2: MAD: Cohort 8 (Fed)Part 2-MAD: Cohort 9 (Fed)Part 2-MAD: Cohort 10 (Fed)Part 2-MAD: Cohort 11 (Fed)Part 2-MAD: Placebo (Fed)Total
Mean75.77 ± 11.3176.47 ± 20.4482.50 ± 12.2777.90 ± 6.6682.43 ± 13.8479.80 ± 19.9078.15 ± 14.2076.03 ± 11.6185.07 ± 3.0077.17 ± 4.5386.69 ± 11.7777.40 ± 12.67279.35 ± 15.16179.6 ± 12.82
Height
Height(cm)Part 1-SAD: Cohort 1 (30mg, Fed)Part 1-SAD: Cohort 2 (100mg, Fed)Part 1-SAD: Cohort 3 (300mg, Fed and Fasted for Food Effect)Part 1-SAD: Cohort 4 (600mg, Fed)Part 1-SAD: Cohort 5 (1200mg, Fed)Part 1-SAD: Cohort 6 (2000mg, Fed)Part 1-SAD: Placebo (Fed and Fasted for Food Effect)Part 2-MAD: Cohort 7 (Fed)Part 2: MAD: Cohort 8 (Fed)Part 2-MAD: Cohort 9 (Fed)Part 2-MAD: Cohort 10 (Fed)Part 2-MAD: Cohort 11 (Fed)Part 2-MAD: Placebo (Fed)Total
Mean167.05 ± 13.24169.42 ± 14.11168.51 ± 9.73168.95 ± 10.22175.05 ± 10.73177.93 ± 13.08172.54 ± 13.05169.78 ± 9.16175.68 ± 6.90170.02 ± 7.20167.79 ± 8.24167.40 ± 12.12171.30 ± 13.04170.89 ± 11.04
08

Study locations

1 site
  • Spaulding Clinical, LLC
    West Bend, Wisconsin 53095, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Mar 2025, 26 months.

Results were first posted in May 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2023
First posted
Feb 21, 2023
StartActual
Jan 23, 2023
Primary completionActual
Mar 28, 2025
CompletionActual
Mar 28, 2025
Results first posted
May 1, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05735249
Lead sponsor
Arisan Therapeutics, Inc.
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Jan 23, 2023
Primary completion
Mar 28, 2025
Completion
Mar 28, 2025
Results posted
May 1, 2026
Last update
May 1, 2026

Study contacts

Ken McCormack, PhD
study chair · Arisan Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARN-75039

Start the discussion